99 related articles for article (PubMed ID: 1999717)
1. Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration.
Feun LG; Gonzalez R; Savaraj N; Hanlon J; Collier M; Robinson WA; Clendeninn NJ
J Clin Oncol; 1991 Mar; 9(3):464-7. PubMed ID: 1999717
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma.
Feun LG; Robinson WA; Savaraj N; Gonzalez R; Liebmann A; Offenhauser K; Clendeninn NJ
Am J Clin Oncol; 1995 Dec; 18(6):488-90. PubMed ID: 8526190
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder.
Khorsand M; Lange J; Feun L; Clendeninn NJ; Collier M; Wilding G
Invest New Drugs; 1997; 15(2):157-63. PubMed ID: 9220296
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies.
Feun LG; Savaraj N; Benedetto P; Hanlon J; Sridhar KS; Collier M; Richman S; Liao SH; Clendeninn NJ
J Natl Cancer Inst; 1991 Jan; 83(1):51-5. PubMed ID: 1984518
[TBL] [Abstract][Full Text] [Related]
5. Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule.
Adamson PC; Balis FM; Miser J; Arndt C; Wells RJ; Gillespie A; Aronson L; Penta JS; Clendeninn NJ; Poplack DG
Cancer Res; 1992 Feb; 52(3):521-4. PubMed ID: 1732038
[TBL] [Abstract][Full Text] [Related]
6. A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.
de Vries EG; Gietema JA; Workman P; Scott JE; Crawshaw A; Dobbs HJ; Dennis I; Mulder NH; Sleijfer DT; Willemse PH
Br J Cancer; 1993 Sep; 68(3):641-4. PubMed ID: 8353055
[TBL] [Abstract][Full Text] [Related]
7. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
Bleehen NM; Newlands ES; Lee SM; Thatcher N; Selby P; Calvert AH; Rustin GJ; Brampton M; Stevens MF
J Clin Oncol; 1995 Apr; 13(4):910-3. PubMed ID: 7707118
[TBL] [Abstract][Full Text] [Related]
8. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T
J Clin Oncol; 1992 Dec; 10(12):1919-26. PubMed ID: 1280673
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of tauromustine administered in a weekly schedule.
Gjedde SB; Mouridsen HT; L-Madsen E; Jensen NV; Blomquist E; Bergh J; Söderberg M; Wählby S
Eur J Cancer; 1993; 29A(13):1901-2. PubMed ID: 8260251
[TBL] [Abstract][Full Text] [Related]
10. Oral piritrexim, an effective treatment for metastatic urothelial cancer.
de Wit R; Kaye SB; Roberts JT; Stoter G; Scott J; Verweij J
Br J Cancer; 1993 Feb; 67(2):388-90. PubMed ID: 8431372
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
12. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
[TBL] [Abstract][Full Text] [Related]
13. A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Hamid O; Ilaria R; Garbe C; Wolter P; Maio M; Hutson TE; Arance A; Lorigan P; Lee J; Hauschild A; Mohr P; Hahka-Kemppinen M; Kaiser C; Turner PK; Conti I; Grob JJ
Cancer; 2014 Jul; 120(13):2016-24. PubMed ID: 24676877
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
[TBL] [Abstract][Full Text] [Related]
15. Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule.
Adamson PC; Balis FM; Miser J; Wells RJ; Bleyer WA; Williams TE; Gillespie A; Penta JS; Clendeninn NJ; Poplack DG
Cancer Res; 1990 Aug; 50(15):4464-7. PubMed ID: 2369724
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma.
Margolin KA; Doroshow JH; Akman SA; Leong LA; Morgan RJ; Somlo G; Raschko J; Pereira C; Yonemoto L; Ahn C
J Clin Oncol; 1992 Oct; 10(10):1574-8. PubMed ID: 1403037
[TBL] [Abstract][Full Text] [Related]
17. A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U).
Weiss GR; Sarosy GA; Shenkenberg TD; Williams T; Clendeninn NJ; Von Hoff DD; Woolley JL; Liao SH; Blum MR
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1867-73. PubMed ID: 2632268
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of tauromustine in disseminated malignant melanoma.
Nolte H; Gjedde SB; Lindegaard-Madsen E; Bergh J; Blomquist E; Mouridsen HT
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):655-7. PubMed ID: 2714342
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma.
Bleehen NM; Newman HV; Rampling RP; Ramsay JR; Roberts JT; Bedford P; Nethersell AB
Br J Cancer; 1995 Sep; 72(3):766-8. PubMed ID: 7669591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
